Products

Clinical Diagnostic Tests

FEMERIS has created a product development program using guidelines from CLIA and CLSI with the goal to efficiently bring sensitive and specific testing into the clinical diagnostic lab. Our product development begins with investment in basic research to identify and validate potential biomarkers. The next phase includes applied research to translate these findings into useable diagnostic tools. We then test our diagnostic assays in a prospective clinical trial before final transfer to our clinical diagnostic laboratory or other partners for commercialization.

Patents

Gygax SE, Vermitsky J-P, Chadwick SG, Self MJ, Mordechai E, Adelson ME. A Method for Determining Azole Resistance in Candida glabrata. Patent No. US 8,021,846 issued September 20, 2011.

Gygax SE, Chadwick SG, Prasad A, Adelson ME, Mordechai E. (2012) Novel Single Nucleotide Polymorphisms and Community-associated Methicillin Resistant Staphylococcus aureus. US Patent (USPTO Pub. No.: US 2012/0009572)

Gygax SE, Overmyer CL, Desalvia LA, Adelson ME, Mordechai E. (2011) Method of Determining Types I, II, III, IV, and V Methicillin-Resistant Staphylococcus aureus (MRSA) in a Biological Sample. US Patent (USPTO Pub. No.: US 2011/0312876)

Gygax SE, Prasad A, Adelson ME, Mordechai E. (2010) Detection of Penicillin Tolerance in Group B Streptococcus: Single Nucleotide Polymorphisms in Penicillin Binding Protein 4. US Patent (USPTO Pub. No.: 2010/0028884).

4/2012 - Announcing new testing for Aerobic Vaginitis

4/2012 - Announcing a Complimentary Reflex Test to Determine Metronidazole Resistance in Trichomonas vaginalis

1/2012 - FEMERIS scientist, Dr. David Hilbert, had a manuscript entitled "Clinical Escherichia coli isolates utilize alpha-hemolysin to inhibit in vitro epithelial cytokine production" accepted into the journal Microbes and Infection.

8/2011 - Announcing new Bacterial Vaginosis/Lactobacillus Profiling Assay

6/2011 - Femeris launches endometriosis research focusing on the discovery of new biomarkers for non-invasive diagnostics and validation of novel therapeutic targets for high-throughput small molecule inhibitor screening.

05/2011 - FEMERIS scientist, Dr. David Hilbert, will be presenting his research on the analysis of host antimicrobial protein production during bacterial vaginosis at the 112th American Society for Microbiology Conference in New Orleans, LA.

04/2011 - FEMERIS scientists will be attending the 2011 American College of Obstetrics and Gynecology conference in Washington D.C.

12/2010 - FEMERIS developed a Urinary Tract Infection Antibiotic Susceptibility assay for the Enterobacteriaceae Escherichia coli, Klebsiella spp., and Proteus mirabilis for Medical Diagnostic Laboratories.

11/2010 - FEMERIS scientist, Dr. Sergey Balashov, presented his research on Neisseria gonorrhoeae antibiotic susceptibility testing at the Association for Molecular Pathology Conference in San Jose, CA.

09/2010 - FEMERIS scientist, Dr. Scott Gygax, presented his research on Methicillin-Resistant Staphylococcus aureus at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy in Boston, MA.

Products

Clinical Diagnostic Tests

Patents

Latest News